You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

Introduction

This curriculum is intended to build confidence in applying strategies for the prevention and management of thromboembolic disease and to ensure best practices across all clinical indications and care settings. Adherence concerns and patient uncertainty can be alleviated by ensuring that patients are educated by their provider on the differences between non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin, why monitoring is not required for NOACs, and the importance of adherence to prescribed therapy.

Activities

The Real Clinicians of VTE

Steering Committee

Steering Committee Chair
  • Michael B. Streiff, MDMichael B. Streiff, MD
    Associate Professor,
    Johns Hopkins Medicine,
    Baltimore, Maryland
Steering Committee Members
  • Jack E. Ansell, MDJack E. Ansell, MD
    Professor of Medicine,
    Hofstra North Shore/LIJ
    School of Medicine,
    Hempstead, New York
  • Elaine M. Hylek, MD, MPHElaine M. Hylek, MD, MPH
    Professor of Medicine
    Boston University
    School of Medicine,
    Boston, Massachusetts
  • Alok A. Khorana, MDAlok A. Khorana, MD
    Professor of Medicine,
    Cleveland Clinic Lerner
    College of Medicine,
    Case Western Reserve University;
    Sondra and Stephen Hardis
    Chair in Oncology Research,
    Vice Chair (Clinical Services);
    Director, GI Malignancies Program,
    Taussig Cancer Institute,
    Cleveland Clinic,
    Cleveland, Ohio
  • Manesh R. Patel, MDManesh R. Patel, MD
    Associate Professor of Medicine,
    Duke University School of Medicine,
    Durham, North Carolina
  • Alex C. Spyropoulos, MDAlex C. Spyropoulos, MD
    Professor of Medicine,
    Hofstra North Shore-LIJ
    School of Medicine,
    Hempstead, New York
Supported by an independent educational
grant from
Janssen Pharmaceuticals
Developed through a collaboration between Medscape and
Johns Hopkins
Polling Question

How does your institution utilize scored venous thromboembolism (VTE) risk assessment models to manage thromboprophylaxis in hospitalized medical patients?
It never does
It does but is an optional feature
It is part of the electronic health record (EHR)
Our system uses group-specific VTE prophylaxis strategies

Disclosures

Steering Committee
Michael B. Streiff, MD

Participation by Dr Streiff as an advisor does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

Michael B. Streiff, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals; Portola Pharmaceuticals, Inc.

Served as a paid member of committee, panel, or board for BiO2 Medical Inc.

Jack E. Ansell, MD

Jack E. Ansell, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alere; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals; Instrumentation Laboratory; Perosphere; Pfizer Inc; Roche
Owns equity in: Perosphere

Elaine M. Hylek, MD, MPH

Elaine M. Hylek, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals; Medtronic, Inc.; Pfizer Inc
Received honoraria from: Bayer HealthCare Pharmceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company

Alok A. Khorana, MD

Alok A. Khorana, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AngioDynamics, Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Halozyme Therapeutics; Janssen Pharmaceuticals; Leo Pharma Inc.; Pfizer Inc; Roche
Served as a paid member of committee, panel, or board for Janssen Pharmaceuticals; Leo Pharma Inc.

Manesh R. Patel, MD

Manesh R. Patel, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer HealthCare Pharmaceuticals; Genzyme Corporation; Merck & Co., Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; MAQUET, Inc.

Alex C. Spyropoulos, MD

Alex C. Spyropoulos, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer Healthcare, Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals; Pfizer Inc
Received grants for clinical research from Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals